CoQ10 / Ubiquinol
Coenzyme Q10 · Ubidecarenone · Mitochondrial Electron Carrier
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
Grade 3 (mixed/moderate RCT) as a general supplement, with a stronger case as a heart-failure adjunct where the single-best evidence sits at grade 3-4. The heart-failure signal rests mainly on Q-SYMBIO (Mortensen 2014, JACC Heart Failure), a 420-patient, 2-year, double-blind RCT of 300 mg/day that reduced major adverse cardiovascular events (HR 0.50, 95% CI 0.32-0.80, p=0.003), all-cause mortality (10% vs 18%, p=0.018) and cardiovascular mortality (9% vs 16%, p=0.026); this is the cleanest single supplement trial in heart failure, though it is one moderately sized study awaiting independent replication. Statin-myalgia evidence is genuinely mixed: a 2018 meta-analysis of 12 RCTs / 575 patients (Qu, JAHA) found symptomatic improvement in muscle pain, weakness, cramping and fatigue but no change in creatine kinase, while a 2020 meta-analysis (Kennedy, Atherosclerosis, 7 trials / 321 patients) found no benefit for myalgia, and pooled results are dominated by small trials with subjective endpoints. Migraine prophylaxis is modest at best: several small positive RCTs exist, but a pooled analysis of 6 RCTs / 371 participants found no difference in headache severity versus placebo, so the honest read is weaker than the older library rating implied.
- FDA
- Legal supplement; Rx (Japan congestive heart failure)
- WADA
- Not prohibited
Reference only. Not medical advice.
What can go wrong
Generally very safe at 100-300 mg/day; mild GI upset at higher doses, a real warfarin (INR-lowering) interaction, and additive blood-pressure lowering with antihypertensives.
Coenzyme Q10 is a fat-soluble molecule the body makes itself, where it shuttles electrons through the mitochondrial respiratory chain and works as a lipid antioxidant. Its strongest human evidence is as a heart-failure adjunct, resting largely on the Q-SYMBIO trial, which is the closest any supplement has come to a mortality signal in that setting. For the uses people most often buy it for, statin muscle complaints and migraine, the evidence is genuinely mixed and often null in the larger meta-analyses. Blood levels fall with age and drop measurably during statin therapy, which is real biochemistry, though a lower level does not automatically translate into a symptom a capsule will fix. Absorption is poor and erratic no matter which form you take, and the ubiquinol premium is oversold.
The mitochondrial cofactor with the cleanest heart-failure meta-analysis of any supplement.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Coenzyme Q10 is a benzoquinone with a 10-isoprenoid lipid tail that resides in the inner mitochondrial membrane, where it shuttles electrons between Complex I/II and Complex III of the electron transport chain. Without CoQ10, the ATP-generating machinery of every cell stalls. The body synthesizes it endogenously through a multi-step pathway that shares early steps with cholesterol synthesis (the mevalonate pathway), which is why HMG-CoA reductase inhibitors (statins) reduce both endogenous cholesterol AND endogenous CoQ10 production. This biochemical fact is undisputed; the clinical significance for statin myopathy is what remains contested between functional medicine and mainstream cardiology. CoQ10 exists in two interconvertible redox forms: ubiquinone (oxidized) and ubiquinol (reduced). Ubiquinol is the form that actively donates electrons; the body recycles between the two states continuously. Most clinical trials have used the oxidized ubiquinone form, which the body converts to ubiquinol after absorption. Ubiquinol supplements arrived on the market in the 2000s with claims of "pre-reduced" superior absorption. Head-to-head pharmacokinetic studies show ubiquinol does produce somewhat higher plasma levels per equivalent dose, but whether this translates to clinically distinguishable outcomes is genuinely unsettled. Both forms have positive trial signals; the ubiquinol-versus-ubiquinone debate is more commercial than therapeutic for most use cases.
How it is taken
CoQ10 is fat-soluble; absorption is meaningfully enhanced by taking with a meal containing dietary fat. Doses split twice or three times daily maintain higher steady-state plasma levels than single large doses. Pharmacokinetic studies show plasma CoQ10 plateaus at roughly 400-600mg/day single-dose; higher doses do not produce proportionally higher levels. Time to steady-state is 2-4 weeks; clinical effects on cardiovascular and migraine endpoints typically accumulate over 8-12 weeks. Ubiquinone is the form used in major trials and is acceptable for nearly all users. Ubiquinol may be preferred in older adults (60+) whose conversion capacity declines, or in users who don't respond clinically to ubiquinone.
- Heart failure dose
- 100mg three times daily (Q-SYMBIO protocol), with meals
- Migraine prophylaxis
- 100mg three times daily, with meals
- Statin co-supplementation
- 100-200mg/day with the statin or evening meal
- Absorption
- Take with fat-containing meal, non-negotiable for adequate absorption
- Time to effect
- Cardiovascular: 6-12 months. Migraine: 8-12 weeks. Statin myopathy: 4-8 weeks.
- Steady-state
- 2-4 weeks to plateau plasma levels
- Ubiquinol switch
- Consider in users 60+ or non-responders to ubiquinone after 8-12 weeks
- Bedtime question
- No clear superiority for bedtime versus daytime dosing
Which form to buy
Not all preparations of the same ingredient are the same thing, and the trials were run on particular ones.
Ubiquinone (oxidized form)
The form used in essentially every major clinical trial, Q-SYMBIO, KISEL-10, the migraine trials. Cheaper per gram of CoQ10 than ubiquinol. The body interconverts between ubiquinone and ubiquinol continuously; ubiquinone supplementation reliably raises both forms in plasma. Best taken with a fatty meal for absorption.
Ubiquinol (reduced form)
Pre-reduced form launched commercially by Kaneka in 2007. Pharmacokinetic studies show somewhat higher plasma levels per equivalent dose, especially in older adults whose conversion capacity may decline. Whether this translates to better clinical outcomes is genuinely unsettled; most trial evidence is still ubiquinone. Substantially more expensive.
CoQ10 with PrimaVie® / shilajit
Shilajit (a Himalayan resin) contains fulvic acid that supports mitochondrial CoQ10 retention and recycling. Combination products with branded shilajit (PrimaVie) have preliminary evidence for enhanced muscle CoQ10 saturation versus CoQ10 alone.
CoQ10 with piperine / BioPerine
Black pepper extract modestly enhances absorption of fat-soluble compounds including CoQ10. Reasonable add-on for users on lower CoQ10 doses; the absorption benefit is modest.
Solubilized / Liposomal CoQ10
Multiple manufacturers (Q-Gel, MEGA CoQ10, liposomal preparations) market improved bioavailability via phospholipid encapsulation or solubilization. Modest pharmacokinetic advantages documented; clinical outcome differences not consistently shown. Premium pricing.
KanekaQ10® (Kaneka)
Japanese-manufactured pharmaceutical-grade CoQ10 from yeast fermentation. The most-tested branded raw material; many premium consumer brands license Kaneka source. Available as both ubiquinone and ubiquinol forms.
Synthetic CoQ10
Chemically synthesized rather than fermentation-derived. May contain trans-cis isomer mixtures unlike the all-trans natural form. Most reputable brands have moved to fermentation-derived (KanekaQ10 or competing). Worth checking source on the label.
Who it works for, and who it does not
Heart failure patients
Q-SYMBIO is the strongest cardiovascular trial of any supplement for any indication: 300mg/day CoQ10 reduced MACE and mortality in moderate-to-severe heart failure on top of guideline-directed therapy. Should be coordinated with cardiology; not a substitute for ACE inhibitors, beta blockers, MRAs, SGLT2 inhibitors.
Statin users with myopathy
The classical functional-medicine use case. Banach 2018 meta-analysis supports modest muscle-pain reduction; mainstream cardiology has remained skeptical. Many users find CoQ10 enables statin tolerance who otherwise would discontinue, a meaningful clinical outcome even if RCT effect sizes are modest.
Migraine prophylaxis
Real evidence for ~50% migraine frequency reduction at 300mg/day. Included in some neurology guidelines as a complementary option. Effects accumulate over 8-12 weeks. Compares favorably with prescription prophylaxis on safety though typically less effective.
Older women, fertility (IVF)
Bentov-series trials show improved oocyte quality and embryo development markers in women 35+. Underpowered for live birth outcomes but mechanistically plausible (oocyte mitochondrial function declines with age). Coordinate with reproductive endocrinology.
Endurance athletes
Routine performance-enhancement claim. Trials have been mixed; modest improvements in some markers. Likely most relevant for masters athletes where CoQ10 levels have declined with age. Not WADA-prohibited; not a doping concern.
Healthy adults under 50
The bulk of consumer CoQ10 use. Endogenous synthesis is generally adequate in this cohort; supplementation in already-replete users produces modest measurable changes without clearly demonstrated clinical benefit.
Periodontal disease
Topical and oral CoQ10 has preliminary evidence for periodontal inflammation reduction. Effect sizes modest; mainstream dentistry has not adopted. Reasonable adjunct alongside professional care.
Taken with other things
Combinations people actually use. Evidence for one ingredient is not evidence for a pair.
Statins
The canonical functional-medicine pairing. Statins reduce endogenous CoQ10 synthesis; co-supplementation restores levels. Whether this clinically prevents statin myopathy is contested; many users find it enables statin tolerance regardless.
Selenium
KISEL-10 trial used 200mcg selenium + 200mg CoQ10 daily and showed cardiovascular mortality reduction in elderly. Mechanistically complementary (both support glutathione peroxidase and mitochondrial function).
Omega-3 fatty acids
Mechanistically complementary for cardiovascular endpoints. Combination is common in heart-focused protocols. Both fat-soluble; both benefit from co-administration with meal.
Vitamin E
Both lipid-soluble antioxidants with complementary mitochondrial roles. Modest synergy in some trials; mostly considered acceptable to combine.
L-carnitine
Mitochondrial cofactor pairing, carnitine for fatty acid transport into mitochondria, CoQ10 for electron transport. Combination has preliminary evidence in heart failure and fertility contexts.
Warfarin
CoQ10 is structurally similar to vitamin K and may reduce warfarin's anticoagulant effect. Documented interaction; coordinate INR monitoring with prescribing physician.
Antihypertensive medications
CoQ10 can produce modest blood pressure lowering. Additive effect with antihypertensives may produce hypotension in some users. Monitor blood pressure when initiating.
Beta-blockers
Beta-blockers can reduce CoQ10 levels; supplementation is reasonable. Monitor for additive blood-pressure lowering with antihypertensive beta-blockers.
Chemotherapy
Theoretical concern that CoQ10's antioxidant activity could interfere with oxidative-mechanism chemotherapy. Coordinate with oncology rather than self-supplementing during active treatment.
What to look for on the label
Look for: KanekaQ10 (or competing pharmaceutical-grade fermentation source) on the label; "all-trans isomer" disclosure; oil-based softgel formulations for fat-soluble absorption; third-party verification. Avoid: dry tablet CoQ10 (poorly absorbed without dietary fat coordination), unidentified-source CoQ10 (likely synthetic with cis-trans contamination), proprietary blends that obscure CoQ10 content, and dramatically cheap products (the raw material is genuinely expensive).
Safety in detail
- Generally very safe at routine doses. Q-SYMBIO and other major trials used 300mg/day for 2+ years with no clinically meaningful adverse signals.
- Mild GI upset (nausea, diarrhea) is the most common side effect, dose-related and reduced by divided dosing with meals.
- Warfarin interaction is real, CoQ10 has structural similarity to vitamin K and can reduce warfarin's anticoagulant effect. INR monitoring is necessary if both are used.
- Blood-pressure lowering effect is documented and can be clinically meaningful (10+ mmHg systolic in some users). Users on antihypertensives should monitor BP when initiating or changing dose.
- Insulin sensitivity may improve modestly with chronic use; users with diabetes should monitor glucose and may need medication adjustment.
- Chemotherapy interaction is theoretical (antioxidant interference with oxidative-mechanism drugs), coordinate with oncology during active cancer treatment.
- Pregnancy and breastfeeding: not extensively studied; preliminary data is reassuring but routine supplementation is not established standard of care.
- Cardiac arrhythmias: rare reports at very high doses; unclear whether causal or incidental.
What people get wrong
Often saidStatin users need CoQ10 supplementation.
ActuallyThe biochemistry is real (statins deplete endogenous CoQ10). The clinical significance is contested. Modest evidence for myopathy reduction; mainstream cardiology has not adopted routine co-supplementation as standard of care.
Often saidUbiquinol is dramatically better than ubiquinone.
ActuallyPharmacokinetic studies show somewhat higher plasma levels. Clinical outcome differences are not consistently demonstrated. Trial evidence is mostly with ubiquinone. The price premium often exceeds the documented clinical benefit.
Often saidCoQ10 cures heart failure.
ActuallyQ-SYMBIO reduced MACE and mortality on top of standard guideline-directed therapy. It is adjunct, not replacement, for heart failure care. Coordinate with cardiology.
Often saidCoQ10 supplementation will boost everyone's energy.
ActuallyEndogenous synthesis is generally adequate in healthy young adults. The clearest benefits accrue to users with documented decline contexts (heart failure, statin use, age 60+, specific mitochondrial conditions).
Often saidYou can take CoQ10 without food.
ActuallyFat-soluble, absorption is meaningfully reduced without dietary fat. Taking on empty stomach can reduce effective dose substantially.
Often saidAll CoQ10 products are equivalent.
ActuallySource (fermentation vs synthetic), isomer purity (all-trans vs cis-trans mixture), formulation (oil-based vs dry), and dose form (ubiquinone vs ubiquinol) all matter. Kaneka-source fermentation-derived all-trans is the pharmaceutical-grade reference.
Who profits, and who pushes back
American College of Cardiology guidelines
Despite the Q-SYMBIO results, CoQ10 has not been incorporated as a guideline-recommended therapy in heart failure. The reasons cited include trial-quality concerns, limited replication, and the cost-effectiveness question relative to established therapies. The guideline gap is real and worth understanding.
Mainstream statin literature
The biochemistry of statin-induced CoQ10 depletion is undisputed. The clinical question, whether routine co-supplementation prevents statin myopathy, remains contested with mixed trial evidence. Many cardiologists reserve CoQ10 for documented muscle symptoms rather than routine prescribing.
Peter Langsjoen
Tyler, Texas cardiologist with decades of CoQ10 clinical practice. Father of the family's CoQ10 research lineage. Independent academic voice on heart failure applications.
Stephen Sinatra
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Long-standing functional cardiology advocate; has had his own branded supplements. Aggressive marketing voice, useful but commercially conflicted.
Peter Attia
Discusses CoQ10 with measured framing; uses personally, particularly for statin users. Independent academic voice.
Bryan Johnson
Includes CoQ10 in the Blueprint protocol. Commercial-adjacent (sells related products) but not specifically selling CoQ10.
Mark Houston
Mainstream-adjacent cardiologist who has integrated CoQ10 into hypertension and heart failure protocols. Independent academic voice.
Where the research comes from
| Place | Share of published research |
|---|---|
| Japan | 34% |
| United States | 26% |
| Europe | 22% |
| Other | 18% |
Research published from: United States.
How we got here
CoQ10 was first isolated by Frederick Crane at the University of Wisconsin in 1957 from beef heart mitochondria. Karl Folkers at Merck (and later the University of Texas) led the synthesis and pharmacological characterization through the 1960s-80s. Japan was first to embrace CoQ10 clinically, approving it as a prescription drug for congestive heart failure in 1974 (Neuquinon). The US market remained primarily research-grade until the 1990s expansion of dietary supplement availability under DSHEA. Tsuneo Yamamura at Toyama Medical University drove much of the Japanese clinical research program; Folkers continued US advocacy until his 1997 death. The statin myopathy connection was articulated in the 1990s as statin prescriptions expanded dramatically. The biochemistry (shared mevalonate pathway for cholesterol and CoQ10) is unambiguous; the clinical significance has remained contested between functional medicine (uniformly recommending co-supplementation) and mainstream cardiology (typically reserving for documented myopathy). The 2014 Q-SYMBIO trial was a landmark, among the few supplement RCTs to produce hard cardiovascular endpoints (mortality reduction) on top of standard guideline-directed therapy. The trial reshaped the heart failure conversation around CoQ10, though adoption into formal heart failure guidelines remains slow. Kaneka Corporation's 2007 launch of ubiquinol (the pre-reduced form) created a substantial new commercial category, and a parallel debate over whether the form differential matters clinically.
- 1957Frederick Crane isolates CoQ10 at University of Wisconsin
- 1960s-80sKarl Folkers leads US synthesis and clinical characterization
- 1974Approved as Rx drug for congestive heart failure in Japan (Neuquinon)
- 1990sStatin-CoQ10 depletion mechanism articulated as statin use expands
- 2005Sandor migraine prophylaxis trial
- 2007Kaneka launches ubiquinol, pre-reduced form
- 2013KISEL-10 Swedish elderly trial shows cardiovascular mortality reduction
- 2014Q-SYMBIO landmark heart failure trial, MACE and mortality reduction
- 2018Banach statin myopathy meta-analysis
- 2020sMitochondrial aging and fertility applications expand research interest
What we do not know
- Whether the ubiquinol-versus-ubiquinone differential matters clinically for most users, or only in specific cohorts (older adults, non-responders).
- Whether the Q-SYMBIO results generalize to heart failure with preserved ejection fraction (HFpEF), which has different pathophysiology than the predominantly HFrEF Q-SYMBIO population.
- Whether routine statin co-supplementation should be standard of care for all statin users, or reserved for documented myopathy.
- Whether the Bentov-style fertility findings translate to live-birth improvements in larger trials.
- Whether CoQ10 has a role in the broader mitochondrial-dysfunction-in-aging hypothesis, or is specific to known-decline contexts (heart failure, statins, age).
- How to identify the subset of users with low baseline plasma CoQ10 who appear to benefit most.
Legal status
Universally available globally as a dietary supplement. Approved as a pharmaceutical for congestive heart failure in Japan since 1974 (Neuquinon). Prescribed in some European countries for specific indications. No regulatory restrictions on supplement-grade products. Among the more expensive supplements per dose due to manufacturing complexity (yeast fermentation, isoprenoid chain synthesis), pharmaceutical-grade Kaneka source raw materials drive much of the premium-product pricing.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
KanekaQ10® (Kaneka Corporation, Japan) is the dominant pharmaceutical-grade raw material, fermentation-derived all-trans isomer with extensive purity documentation. Most premium consumer brands license Kaneka source. Synthetic CoQ10 (cis-trans isomer mixtures) was historically more common and is mostly out of the premium market but persists in lower-tier products. The natural all-trans form is what the body uses; cis isomers are not biologically active. Disclosure of fermentation source on the label is a meaningful quality signal. Pharmaceutical pricing in Japan (where it's a Rx drug) is in a different cost structure than US supplement pricing.
At a glance
- Active form
- Ubiquinol (reduced); reversibly converted from ubiquinone
- Tissue location
- All cell mitochondria; highest in heart, liver, kidney
- Heart failure dose
- 300mg/day divided (Q-SYMBIO)
- Migraine dose
- 300mg/day divided (Sandor)
- Maintenance dose
- 100-200mg/day
- Time to plasma steady-state
- 2-4 weeks
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about CoQ10 / Ubiquinol. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
Q-SYMBIO: 420 patients, 300 mg/day, 2 years, MACE HR 0.50 (95% CI 0.32-0.80, p=0.003), all-cause mortality 10% vs 18% and CV mortality 9% vs 16%
Mortensen et al., JACC: Heart Failure (Q-SYMBIO primary report)
Meta-analysis pooling CoQ10 heart-failure trials found reduced mortality (RR 0.69, 95% CI 0.50-0.95)
Q-SYMBIO European sub-group: significant improvement in ejection fraction, NYHA class and both all-cause and CV mortality
Mortensen et al., Q-SYMBIO European sub-group analysis (PMC)
2018 meta-analysis, 12 RCTs / 575 patients: CoQ10 improved statin-associated muscle pain, weakness, cramping and fatigue but did not change creatine kinase
2020 meta-analysis, 7 RCTs / 321 patients: no benefit of CoQ10 supplementation for statin-associated myalgia
Migraine prophylaxis: pooled analysis of 6 small RCTs / 371 participants found no difference in headache severity versus placebo; effect, where seen, emerges around 12 weeks
An Update on Nutraceuticals for Migraine Management, Practical Neurology
Intestinal absorption of CoQ10 is highly variable and largely independent of whether the ubiquinol or ubiquinone form is administered
The Plasma Bioavailability of Coenzyme Q10 Absorbed from the Gut and the Oral Mucosa (PMC)
Comparative bioavailability of CoQ10 formulations varies significantly between products and individuals in healthy elderly subjects
Comparative Bioavailability of Different Coenzyme Q10 Formulations (PMC)
CoQ10 discovered 1957 by Frederick Crane; structure determined 1958 by Karl Folkers at Merck; benzoquinone ring with 10 isoprene units
Frederick Loring Crane (1925-2016) obituary/biography, Photosynthesis Research (Springer)
Clinical overview of CoQ10 in cardiovascular disease, history, statin depletion and prescription use in Japan
CoQ10 for cardiovascular disease review including warfarin interaction and safety context
Coenzyme Q10 for Patients With Cardiovascular Disease: JACC Focus Seminar (ScienceDirect)
The studies that matter
Folkers and Yamamura series1960s-80s
Foundational pharmacokinetic and clinical work establishing CoQ10's role in mitochondrial function and the first cardiovascular trials. Karl Folkers (USA) and Yamamura (Japan) drove parallel research programs.
Q-SYMBIO trial2014
Multi-center European trial in moderate-to-severe heart failure: 300mg CoQ10 daily reduced major adverse cardiovascular events by ~43% and all-cause mortality by 42% at two years versus placebo on top of standard heart failure therapy.
KISEL-10 Swedish elderly trial2013
Selenium + 200mg CoQ10 daily for 4 years in healthy Swedish elderly: reduced cardiovascular mortality. Follow-up at 10 years showed persistent benefit. Combination intervention; CoQ10-alone effect cannot be cleanly isolated.
Sander Cochrane heart failure review2012
Earlier systematic review concluded evidence was modest and inconsistent, predating Q-SYMBIO. The post-Q-SYMBIO meta-analytic landscape has been considerably more favorable.
Sandor migraine prophylaxis2005
100mg three times daily reduced migraine frequency by ~50% versus placebo over 3 months. The most-cited migraine RCT and the basis for inclusion in some neurology guidelines.
Banach statin myopathy meta-analysis2018
Pooled 12 RCTs in statin-intolerant patients: modest reduction in muscle pain with CoQ10 supplementation. The headline finding has been contested by subsequent reviews using different inclusion criteria.
Bentinger and Tekle Q-SYMBIO follow-up analyses2015-2019
Subgroup analyses suggesting effects were largest in patients with documented low baseline plasma CoQ10. The "treat to target" framing rather than universal supplementation.
Bentov fertility / oocyte quality trials2014-2018
Multiple small trials in older women undergoing IVF: CoQ10 supplementation improved oocyte quality markers and embryo development. Promising but underpowered for live-birth outcomes.